AB0517 CORRELATION BETWEEN PATIENT-REPORTED OUTCOMES OF HEALTH-RELATED QUALITY OF LIFE AND CLINICAL ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

Background: Patient-Reported Outcomes (PROs) allow us to know the way the disease could affect patients, and maybe could not be detected in clinical measures. Among these, PROs of health-related quality of life (PRO-QL) represents patient evaluation of its health status and treatment, which affects the functional, psychological, social and emotional capabilities. In fact, patients with the same health status could show different PROs-QL. In the case of systemic lupus erythematoSus (SLE), patients experience many inflammatory symptoms and all of them can affect the health-related quality of life in different ways. Objectives: We aimed to measure the PRO-QL in SLE patients and correlate them with the clinical activity of the disease. Methods: A cross-sectional observational study with SLE patients diagnosed according to SLICC 2012 criteria was performed. In all cases SLEDAI score was carried out, and patients full-filled questionnaires of fatigue (FACIT-FATIGUE), quality of life (EQ-5D-5L), disability (HAQ) and a Global Health Status Scale (GHS) (0-100). Biostatistical analysis with software R was performed, using the multivariate analysis of variance by Pillai test. Results: 54 SLE patients (91.84% female) participated in the study, with a mean age at diagnosis of 27.55±13.21 years and a mean time of disease evolution of 20.45±9.7 years. Mean SLEDAI score was 6.63±6.89, with a 37.04% of patients with SLEDAI>6. The 64.66% of patients were under glucocorticoid treatment, 38.77% under immunosupressants (methotrexate, azatioprine o mycophenolate) and 51.02% under antimalarials. Patients showed a mean score of 34.02±12.38 in FACIT-FATIGUE, 0.72±0.26 in EQ-5D-5L, 0.62±0.71 in HAQ and 64.02±25.93 in GHS. Statistical analysis showed correlation between SLEDAI score and the four questionnaires of PROs-QL (P Conclusion: We observed a correlation between PROs-QL full-filled by SLE patients with the clinical activity of the disease, independently of glucocorticoid treatment, antimalarials and inmunosupressants, the age and the disease evolution. Disclosure of Interests: None declared